ERBB3 Overexpression is Enriched in Diverse Patient Populations with Castration-sensitive Prostate Cancer and is Associated with a Unique AR Activity Signature.
Jordan E VellkyBrenna J KirkpatrickLisa C GutgesellMathias MoralesRyan M BrownYaqi WuMark G Maienschein-ClineLucia D NotardonatoMichael S WeinfeldRyan H NguyenEileen BristerMaria SverdlovLi LiuZiqiao XuSteven KregelLarisa NonnDonald J Vander GriendNatalie M ReizinePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
In diverse patient populations with CSPC, ERBB3 OE was associated with high AR signaling despite low intraprostatic androgen. Mechanistic studies demonstrated a direct link between HER3 and enzalutamide resistance. ERBB3 OE as a biomarker could thus stratify patients for intensification of therapy in castration-sensitive disease, including targeting HER3 directly to improve sensitivity to AR-targeted therapies.